Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Rev Allergy Immunol ; 62(3): 519-533, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35275334

ABSTRACT

Among the new biological therapies for atopic diseases, dupilumab is a fully human monoclonal antibody directed against IL-4Rα, the common chain of interleukin-4 and interleukin-13 receptors. Dupilumab showed clinical improvements in patients with atopic dermatitis, asthma, and chronic rhinosinusitis and is currently under development for other indications. While dupilumab is considered to be well tolerated, a number of recent publications have reported various adverse events. This review aims to summarize the current knowledge about these adverse events, which may help clinicians to improve the follow-up of patients on dupilumab. Injection-site reactions are the most common reported adverse event. However, dupilumab has also been shown to cause ophthalmic complications (e.g., dry eyes, conjunctivitis, blepharitis, keratitis, and ocular pruritus), head and neck dermatitis, onset of psoriatic lesions, progression of cutaneous T-cell lymphoma exacerbation, alopecia areata, hypereosinophilia, and arthritis. Most are managed during dupilumab treatment continuation, but some (e.g., severe conjunctivitis) may result in a discontinuation of treatment. Their molecular origin is unclear and requires further investigations. Among other hypothesis, it has been suggested that T helper (Th)2-mediated pathway inhibition may worsen Th1/Th17-dependent immune responses. An ophthalmological examination for the presence of potential predictive indicators of ophthalmic adverse events is recommended before initiation of dupilumab therapy.


Subject(s)
Asthma , Conjunctivitis , Dermatitis, Atopic , Antibodies, Monoclonal, Humanized/adverse effects , Conjunctivitis/diagnosis , Conjunctivitis/drug therapy , Dermatitis, Atopic/diagnosis , Humans
2.
Sci Rep ; 11(1): 13195, 2021 06 23.
Article in English | MEDLINE | ID: mdl-34162976

ABSTRACT

Chromatin organization within the nuclear volume is essential to regulate many aspects of its function and to safeguard its integrity. A key player in this spatial scattering of chromosomes is the nuclear envelope (NE). The NE tethers large chromatin domains through interaction with the nuclear lamina and other associated proteins. This organization is perturbed in cells from Hutchinson-Gilford progeria syndrome (HGPS), a genetic disorder characterized by premature aging features. Here, we show that HGPS-related lamina defects trigger an altered 3D telomere organization with increased contact sites between telomeres and the nuclear lamina, and an altered telomeric chromatin state. The genome-wide replication timing signature of these cells is perturbed, with a shift to earlier replication for regions that normally replicate late. As a consequence, we detected a higher density of replication forks traveling simultaneously on DNA fibers, which relies on limiting cellular dNTP pools to support processive DNA synthesis. Remarkably, increasing dNTP levels in HGPS cells rescued fragile telomeres, and improved the replicative capacity of the cells. Our work highlights a functional connection between NE dysfunction and telomere homeostasis in the context of premature aging.


Subject(s)
Chromatin/ultrastructure , Deoxyribonucleotides/metabolism , Lamin Type A/physiology , Nuclear Lamina/pathology , Progeria/genetics , Telomere Homeostasis/genetics , Telomere/pathology , Adult , Animals , Cells, Cultured , Cellular Senescence/genetics , DNA Damage , DNA Replication , Fibroblasts , Genes, Reporter , Green Fluorescent Proteins , Histone Code , Humans , Infant, Newborn , Lamin Type A/analysis , Lamin Type A/deficiency , Lamin Type A/genetics , Lamin Type B/analysis , Mice , Mice, Knockout , Progeria/pathology , Recombinant Fusion Proteins/metabolism , Skin/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...